Edition:
Deutschland

Trovagene Inc (TROV.OQ)

TROV.OQ on NASDAQ Stock Exchange Capital Market

1.14USD
23 Jun 2017
Change (% chg)

$-0.16 (-12.31%)
Prev Close
$1.30
Open
$1.31
Day's High
$1.45
Day's Low
$1.14
Volume
2,641,137
Avg. Vol
103,328
52-wk High
$5.97
52-wk Low
$0.62

TROV.OQ

Chart for TROV.OQ

About

Trovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform... (more)

Buy/Sell

Sell Hold Buy
2.00 Mean rating from 1 analysts

Overall

Beta: 0.56
Market Cap(Mil.): $35.31
Shares Outstanding(Mil.): 30.97
Dividend: --
Yield (%): --

BRIEF-Trovagene reports agreement to utilize trovera® ctdna tests and services in cancer clinical trials

* Trovagene announces agreement with global biopharmaceutical company to utilize trovera® ctdna tests and services in cancer clinical trials

BRIEF-Trovagene enters into agreement with Astrazeneca to utilize Trovera CTDNA test and services in prospective biomarker study

* Trovagene enters into agreement with astrazeneca to utilize trovera® ctdna test and services in prospective biomarker study

BRIEF-Trovagene says received notice of default from Oxford Finance LLC

* Trovagene - on June 1, co received notice of event of default from oxford finance llc with respect to that certain loan and security agreement dated as of june 30, 2014

BRIEF-Trovagene says Phase 1 safety study supports planned development of PCM-075 in AML

* Phase 1 safety study supports planned development of PCM-075 in AML

BRIEF-Trovagene announces Q1 loss per share $0.32

* Trovagene announces first quarter 2017 company highlights and financial results

BRIEF-Trovagene reports Q4 loss per share $0.34

* Trovagene reports fourth quarter and year end 2016 financial results

BRIEF-Trovagene, Nerviano announce license agreement for therapeutic candidate PCM-075

* Trovagene and Nerviano announce license agreement for therapeutic candidate PCM-075

BRIEF-Trovagene says publication of trovera kras liquid biopsy test demonstrates clinical utility in advanced cancers for detection and measurement of therapeutic response

* Trovagene - publication of trovera kras liquid biopsy test demonstrates clinical utility in advanced cancers for detection and measurement of therapeutic response Source text for Eikon: Further company coverage:

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie +0.45%
Rohstoffe +0.34%
Industrie +0.08%
Konjunktur abhängige Waren & Dienstleistungen -0.02%
Konjunktur unabhängige Waren & Dienstleistungen -0.09%
Finanzindustrie -0.10%
Pharma +0.66%
Technologie -0.06%
Telekommunikation -0.15%